Special Issue

In Vitro Development of Targeted Drugs and Nanoparticles

Message from the Guest Editor

During the last decades, there has been an increasing focus on the design and development of targeted drugs, including nanotherapeutics. Mostly nanosystems and targeted drugs are being developed for cancer therapy and diagnostics in order to reduce possible toxic effects, improve bioavailability and increase clinical efficiency. However, nanomedicine still receives criticism mainly due to the lack of high affinity with respect to targeted tissue. Thus, more efficient strategies for targeting desirable tissues and combating resistance to therapy are needed. Currently, many actively targeting molecules are being investigated in various models in vitro and in vivo, providing new hope for more specific personalized therapy for many diseases. This Special Issue seeks high quality studies focusing on targeted therapy and nanotechnology applied in personalized therapy areas. Topics include but are not limited to the following:

- Design of new molecules for targeted therapy and diagnostics;
- Development of targeted peptides/antibodies;
- Development of nanocarriers for personalized and precision medicine;
- Development of new nanomaterials for personalized therapy.

Guest Editor

Dr. Vilma Petrikaitė

- 1. Institute of Biotechnology, Vilnius University, V. A. Graičiūno 8, 02241 Vilnius, Lithuania
- 2. Institute of Cardiology, Lithuanian University of Health Sciences, A. Mickeviciaus g. 9, LT44307 Kaunas, Lithuania

Deadline for manuscript submissions

closed (30 September 2022)



Biomolecules

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 9.2
Indexed in PubMed



mdpi.com/si/112652

Biomolecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomolecules@mdpi.com

mdpi.com/journal/biomolecules





Biomolecules

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 9.2 Indexed in PubMed



About the Journal

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in Biomolecules so far. We would be delighted to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA

Author Benefits

Open Access

 free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)

